Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
H&I Critical Care is a specialized pharmaceutical company based in India, operating as a prominent division of Alna Biotech. The company is dedicated to the manufacturing, marketing, and distribution of a comprehensive range of critical care medicines, including injectables, infusions, tablets, and capsules. Its extensive product portfolio features life-saving treatments such as Meropenem, Enoxaparin, and Human Normal Albumin, catering to intensive care units and emergency departments. H&I Critical Care operates primarily through a PCD (Propaganda Cum Distribution) pharma franchise model, providing monopoly rights and marketing support to its partners across India. The company's manufacturing processes adhere to stringent WHO-GMP and ISO 9001 standards, ensuring high quality and efficacy in every dose. By focusing on affordability and innovation in the critical care segment, H&I Critical Care has established itself as a trusted partner for healthcare professionals and hospitals nationwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on H & I Critical Care.